Expanding the Frontiers of Breast Cancer Immunotherapy

Pipette dropping stem cell research fluid on pcr plate. Medical Dropper

Elizabeth A. Mittendorf, MD, PhD, a breast cancer surgeon and international leader in breast cancer vaccines, recently joined Brigham and Women’s Hospital (BWH) from the MD Anderson Cancer Center in Houston, where her research focused on vaccines that target the HER2 protein expressed on many breast tumors. At the Brigham, her work focuses on advancing our understanding of breast cancer immunotherapies.

Read More

Increasing First-Line Treatment Options for Advanced Kidney Cancer

Human kidney cross section on scientific backgroundA drug whose clinical testing was led by Toni K. Choueiri, MD, of Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC), has become a standard first-line therapy for certain newly diagnosed patients with advanced kidney cancer. Additionally, several combination therapies are being used or tested at DF/BWCC and elsewhere against this aggressive cancer.
Read More

Could ‘Precursor Escape’ Explain Advanced High-Grade Serous Carcinoma?

Over a decade ago, Christopher Crum, MD, of Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC), helped design the protocol that revealed the fallopian tubes to be the origin of most high-grade serous carcinomas (HGSCs), the tumor type afflicting over two-thirds of women with ovarian cancer.

Read More

Case Study: Cancer Diagnostic Service (CDS) Expedites Next Steps in Care

For clinically complex patients who present with signs or symptoms of cancer, the Cancer Diagnostic Service (CDS) at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) can expedite a diagnosis and avoid unnecessary testing and delays.

Read More

Center for Oncoendocrinology Provides Care for Cancer Patients with Endocrine Conditions

The Center for Oncoendocrinology at Brigham and Women’s Hospital was established to provide expert endocrine care for cancer patients during and after treatment. Endocrinologists at the Center, a program of Dana-Farber/Brigham and Women’s Cancer Center, can provide specialized knowledge of endocrine issues that may affect your cancer patient.

Read More

Early Diagnosis of Ovarian Cancer via a Blood Test, Aided by Artificial Intelligence

With the help of artificial intelligence, researchers from Brigham and Women’s Hospital (BWH) and Dana-Farber Cancer Institute (DFCI) have developed an early diagnostic tool for ovarian cancer that shows equal sensitivity but far fewer false positives than previous testing strategies. Read More

Thyroid Cancer 360 Program Employs Multifaceted Analyses to Identify Targeted Treatments for Patients with Advanced and Aggressive Thyroid Cancers

Specialists in the Thyroid Cancer Center at Dana-Farber/Brigham and Women’s Cancer Center are providing targeted treatments to improve outcomes for patients with advanced and aggressive thyroid cancers in the new Thyroid Cancer 360 Program. Read More

Pioneering Multiple Myeloma Trials Evaluate Novel Immunologic Approaches for Long-term Disease Control

Hemato-oncologists at the Jerome Lipper Multiple Myeloma Center at Dana-Farber/Brigham and Women’s Cancer Center are leading studies of innovative immunologic approaches for patients with multiple myeloma that are designed to achieve long-term control of the disease. Read More

New Program Offers Personalized Risk Assessment, Screening, and Prevention Strategies for Patients at Increased Risk for Breast Cancer

Specialists from Dana-Farber/Brigham and Women’s Cancer Center, Dana-Farber Cancer Institute, and Brigham and Women’s Hospital recently introduced the Breast Cancer Personalized Risk Assessment, Education and Prevention (B-PREP) Program for patients at increased risk for breast cancer and for patients who want to better understand their risk. Read More

FDA Approves CAR T-Cell Therapy for Non-Hodgkin Lymphoma

Dana-Farber/Brigham and Women’s Cancer is one of few centers in the country certified to offer this new approach.

Following a successful clinical trial involving Dana-Farber Cancer Institute and Brigham and Women’s Hospital, the first chimeric antigen receptor (CAR) T-cell therapy for adult cancers was approved by the Food and Drug Administration (FDA) on Oct.19. Dana-Farber/Brigham and Women’s Cancer Center was the only facility in the northeast to be part of the clinical trial that led to FDA approval and is one of a few locations certified to offer this new therapy nationwide. Read More